Bristol Myers Q2 rev $12.2B (+9%), non-GAAP EPS $2.07, raises FY guidance

BRISTOL MYERS SQUIBB CO

2024-Q2 EPS reported -$5.05 revenue$24,066,000,000

Revenues $12.2B up 9% YoY (+11% ex-FX); Growth Portfolio $5.6B up 18% (+21% ex-FX).
GAAP EPS $0.83, non-GAAP EPS $2.07; includes $(0.04) per share net impact from IPRD and licensing.
Raising 2024 non-GAAP guidance; U.S. approvals of Breyanzi for follicular and mantle cell lymphoma.
Subcutaneous nivolumab under regulatory review in U.S. and E.U.
CEO Boerner cited progress on commercial execution and pipeline advancement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.